• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

My Top Stock Pick for 2020 Is a Super Strong Finisher From 2019

There will be other stocks that do better, but this one has the potential of a big gain but with limited downside.
By JAMES "REV SHARK" DEPORRE
Jan 02, 2020 | 12:00 PM EST
Stocks quotes in this article: AUPH

Choosing a top stock pick for the year ahead is always an interesting exercise. There are a couple different approaches that can be used. If you are trying to choose a stock that will have the largest percentage return, then the best strategy is to select a very low-priced stock that has the potential to jump multi-fold if you are right. A high-risk biotechnology name is often a good choice.

The right low-priced, small-cap stock will almost certainly outperform any well-known big-cap name. The best stocks in the Dow Jones Industrial Average or the S&P 500 will never do better than the best stocks in the Russell 2000 Index of small-cap stocks.

Rather than gamble on some low-priced speculative stock, my approach here is to look for something with solid upside potential but with a lower level of risk. There will be other stocks that do better, but this one has the potential of a big gain but with limited downside. My top pick for 2020 is a stock that I discussed often in 2019: Aurinia Pharmaceuticals Inc. (AUPH) .

In 2019 Aurinia had two big events. The most important was that its drug for the treatment of lupus nephritis achieved very robust results. This is a very large potential market and the stock traded up sharply on the news. Earlier in the year, Aurinia announced superior results for its voclosporin ophthalmic solution that is used for the treatment of dry eye syndrome.

With the strong data from two indications under its belt, the next big move for Aurinia is to start the process of commercializing its drugs. This is where the opportunity lies for the stock.

A large sales force is not needed to market to a small population of nephrologist and the company can undertake that task, but on its conference calls management has stated that it making marketing plans "in the event that we don't get acquired." There are clear hints that management will be looking for a deal.

Indeed, just this morning, after this article was written, Dealreporter issued a "flash note" to its subscribers that Pharmaceutical mergers and acquisitions will likely stay hot in the first half of 2020 and it is keeping an eye on Aurinia Pharmaceuticals in the rare disease area. This is further confirmation of my thesis that Aurinia management is looking for a takeover deal.

Essentially, Aurinia has been largely de-risked due to the strong data on two indications and now the question is how well it can commercialize its success. The upside is that the company is acquired and the stock could double or more if that occurs. If there is no acquisition, the downside is limited as the drug will be commercialized for a very large market by current management.

Aurinia probably won't win a stock-picking contest, but the potential for a sizable gain in 2020 is good.

I'll be posting some other ideas for 2020, but this is one that has the potential for a triple-digit percentage gain with relatively limited risk to the downside.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Rev Shark was long AUPH.

TAGS: Fundamental Analysis | Investing | Small Cap | Stocks | Biotechnology | Healthcare | Pharmaceuticals | Real Money

More from Stocks

Navigating a Market Correction

James "Rev Shark" DePorre
Feb 27, 2021 10:00 AM EST

The most critical factor in long-term market success is the ability to effectively navigate market corrections.

Corrective Action Produces Fading Confidence and Technical Damage

James "Rev Shark" DePorre
Feb 26, 2021 5:08 PM EST

It's dangerous to have too much exposure now, but the potential for a good recovery is there once interest rate issues are digested.

I'm Intrigued by the Recent Pullback in Aurora Mobile

Timothy Collins
Feb 26, 2021 3:30 PM EST

While the Chinese company is still not profitable, it is cash flow positive.

Salesforce Gets a Quant Downgrade on Top of Weakening Charts

Bruce Kamich
Feb 26, 2021 12:50 PM EST

Here's what investors and traders need to think about.

My Preference Right Now Is to Buy Pre-Deals

Timothy Collins
Feb 26, 2021 12:36 PM EST

I've added a few names that I see as a great risk-reward because of the limited downside.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:32 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Navigating a Market Correction
  • 11:29 AM EST GARY BERMAN

    Where Does the Nasdaq Go From Here?

    Where does the Nasdaq Composite (CCMP) index go fr...
  • 12:31 PM EST GARY BERMAN

    Has the Short-Term Top Come for the XLF/Banks?

    The has triggered a long-term overbought signal ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login